| Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes N Esser, S Legrand-Poels, J Piette, AJ Scheen, N Paquot Diabetes research and clinical practice 105 (2), 141-150, 2014 | 2242 | 2014 |
| Fructose and metabolic diseases: new findings, new questions L Tappy, KA Lê, C Tran, N Paquot Nutrition 26 (11-12), 1044-1049, 2010 | 533 | 2010 |
| Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue N Esser, L L’homme, A De Roover, L Kohnen, AJ Scheen, M Moutschen, ... Diabetologia 56, 2487-2497, 2013 | 287 | 2013 |
| Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease N Esser, N Paquot, AJ Scheen Expert opinion on investigational drugs 24 (3), 283-307, 2015 | 283 | 2015 |
| No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant … N Paquot, MJ Castillo, PJ Lefèbvre, AJ Scheen The Journal of Clinical Endocrinology & Metabolism 85 (3), 1316-1319, 2000 | 270 | 2000 |
| Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes AJ Scheen, N Paquot Diabetes & metabolism 39 (3), 179-190, 2013 | 234 | 2013 |
| Mechanisms of dexamethasone-induced insulin resistance in healthy humans L Tappy, D Randin, P Vollenweider, L Vollenweider, N Paquot, ... The Journal of Clinical Endocrinology & Metabolism 79 (4), 1063-1069, 1994 | 209 | 1994 |
| Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages [S] L L'homme, N Esser, L Riva, A Scheen, N Paquot, J Piette, ... Journal of lipid research 54 (11), 2998-3008, 2013 | 188 | 2013 |
| Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes S Legrand-Poels, N Esser, L L’homme, A Scheen, N Paquot, J Piette Biochemical pharmacology 92 (1), 131-141, 2014 | 187 | 2014 |
| Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients J Rodriguez, S Hiel, AM Neyrinck, T Le Roy, SA Pötgens, Q Leyrolle, ... Gut 69 (11), 1975-1987, 2020 | 183 | 2020 |
| Antidiabetic agents: potential anti-inflammatory activity beyond glucose control AJ Scheen, N Esser, N Paquot Diabetes & metabolism 41 (3), 183-194, 2015 | 182 | 2015 |
| Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence AJ Scheen, N Paquot Diabetes & metabolism 40 (6), S4-S11, 2014 | 144 | 2014 |
| How to measure insulin action in vivo A Scheen, N Paquot, MJ Castillo, PJ Lefèbvre Diabetes/metabolism reviews 10 (2), 1994 | 126 | 1994 |
| Link between gut microbiota and health outcomes in inulin-treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial S Hiel, MA Gianfrancesco, J Rodriguez, D Portheault, Q Leyrolle, ... Clinical Nutrition 39 (12), 3618-3628, 2020 | 109 | 2020 |
| Inflammatory markers and cardiometabolic diseases N Esser, N Paquot, AJ Scheen Acta Clinica Belgica 70 (3), 193-199, 2015 | 98 | 2015 |
| Saturated fatty acids induce NLRP3 activation in human macrophages through K+ efflux resulting from phospholipid saturation and Na, K-ATPase disruption MA Gianfrancesco, J Dehairs, L L'homme, G Herinckx, N Esser, O Jansen, ... Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2019 | 81 | 2019 |
| Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes AJ Scheen, N Paquot, PJ Lefèbvre Expert opinion on investigational drugs 26 (12), 1373-1389, 2017 | 77 | 2017 |
| Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa P Delanaye, E Cavalier, RP Radermecker, N Paquot, G Depas, ... Nephron Clinical Practice 110 (3), c158-c163, 2008 | 76 | 2008 |
| Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives AJ Scheen, J De Flines, A De Roover, N Paquot Diabetes & metabolism 35 (6), 537-543, 2009 | 66 | 2009 |
| Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects N Paquot, PH Schneiter, E Jequier, R Gaillard, PJ Lefebvre, A Scheen, ... Diabetologia 39, 580-586, 1996 | 64 | 1996 |
